Skip to main content

Advertisement

SpringerLink
Log in

Osteonecrosis of the jaw related to sunitinib

  • Case Report
  • Published:
Oral and Maxillofacial Surgery Aims and scope Submit manuscript

Abstract

Case Report

A 59-year-old male patient was referred to the hospital with exposed bone measuring 10 mm in diameter in the posterior, left-side region of the lower jaw. Two months previous, the first molar had been extracted. The patient had contracted renal cell carcinoma and had been treated by nephrectomy in 2003. Soft tissue metastases occurred. After initial therapy with interferon and vinblastine, a relapse occurred and the therapy was changed to sorafenib, followed by sunitinib. Osteonecrosis of the lower jaw appeared 1 year after initial and exclusive therapy with sunitinib.

Conclusions

Bisphosphonates had never been applied. With increasing application of multi-kinase inhibitors, complications due to osteonecrosis could occur more frequently.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884–896

    Article  CAS  PubMed  Google Scholar 

  2. Haas NB, Uzzo RG (2007) Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. Curr Treat Options in Oncol 8:211–226

    Article  Google Scholar 

  3. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337

    CAS  PubMed  Google Scholar 

  4. Arora A, Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971–979

    Article  CAS  PubMed  Google Scholar 

  5. Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin C (1993) Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol 143:1377–1388

    CAS  PubMed  Google Scholar 

  6. Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S (2009) Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol 20:600–601

    Article  CAS  PubMed  Google Scholar 

  7. Brunello A, Saia G, Bedogni A, Scaglione D, Basso U (2009) Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 44:173–175

    Article  CAS  PubMed  Google Scholar 

  8. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209–211

    Article  CAS  PubMed  Google Scholar 

  9. Assael LA (2004) New foundations in understanding osteonecrosis of the jaws. J Oral Maxillofac Surg 62:125–126

    Article  PubMed  Google Scholar 

  10. Chrcanovic BR, Reher P, Sousa AA, Harris M (2010) Osteoradionecrosis of the jaws—a current overview—part 1: physiopathology and risk and predisposing factors. Oral Maxillofac Surg 14:3–16

    Article  PubMed  Google Scholar 

  11. Langer CJ (2006) Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: case report. Support Cancer Ther 3:122–124

    Article  CAS  PubMed  Google Scholar 

  12. Walter C, Grotz KA, Kunkel M, Al-Nawas B (2007) Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15:197–202

    Article  PubMed  Google Scholar 

  13. Piesold JU, Al-Nawas B, Grotz KA (2006) Osteonecrosis of the jaws by long term therapy with bisphosphonates. Mund Kiefer Gesichtschir 10:287–300

    Article  PubMed  Google Scholar 

  14. Heinrich MC, Blanke CD, Druker BJ, CC L (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692–1703

    Article  CAS  PubMed  Google Scholar 

  15. Schmidt-Arras D, Schwable J, Bohmer FD, Serve H (2004) Flt3 receptor tyrosine kinase as a drug target in leukemia. Curr Pharm Des 10:1867–1883

    Article  CAS  PubMed  Google Scholar 

  16. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24

    Article  CAS  PubMed  Google Scholar 

  17. Wolter P, Dumez H, Schoffski P (2007) Sunitinib and hypothyroidism. N Engl J Med 356:1580; author reply 1580–1581

  18. Roodhart JM, Langenberg MH, Witteveen E, Voest EE (2008) The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3:132–143

    Article  CAS  PubMed  Google Scholar 

  19. Suwattee P, Chow S, Berg BC, Warshaw EM (2008) Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis. Arch Dermatol 144:123–125

    Article  PubMed  Google Scholar 

  20. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35

    Article  CAS  PubMed  Google Scholar 

  21. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G (2007) Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1:S41–S54

    CAS  PubMed  Google Scholar 

  22. Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54:1066–1072

    Article  PubMed  Google Scholar 

  23. Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, Kirkpatrick CJ (2007) Actinomycosis of the jaws—histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 451:1009–1017

    Article  PubMed  Google Scholar 

  24. Schwartz HC (1982) Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 4:251–253

    Article  CAS  PubMed  Google Scholar 

  25. Marquet P, Lachatre G, Debord J, Eichler B, Bonnaud F, Nicot G (1992) Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 42:545–547

    Article  CAS  PubMed  Google Scholar 

  26. Billiau A (1981) Pharmacokinetic and pharmacological aspects of interferon therapy in man. Acta Microbiol Acad Sci Hung 28:257–262

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oral and Maxillofacial Surgery, University Medical Centre of the Johannes Gutenberg University, Mund-, Kiefer-und Gesichtschirurgie, Augustusplatz 2, 55131, Mainz, Germany

    Felix P. Koch, Christian Walter & Wilfried Wagner

  2. Institute of Pathology, University Medical Centre of the Johannes Gutenberg University, Mainz, Germany

    Torsten Hansen

  3. Clinic for Oncology and Haematology, Krankenhaus Nordwest, Frankfurt a.M., Germany

    Elke Jäger

Authors
  1. Felix P. Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Torsten Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elke Jäger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wilfried Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felix P. Koch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koch, F.P., Walter, C., Hansen, T. et al. Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg 15, 63–66 (2011). https://doi.org/10.1007/s10006-010-0224-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10006-010-0224-y

Keywords

Search

Navigation